November 29, 2016 - By Adrian Mccoy
In a research note released on today, Jefferies International reiterated their “Hold” rating on Mediclinic International Plc (LON:MDC)‘s stock. The price target would suggest a potential upside of 4.92% from company’s last price.
Out of 10 analysts covering Mediclinic International (LON:MDC), 3 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 30% are positive. GBX 1170 is the highest target while GBX 741 is the lowest. The GBX 939.50 average target is 32.42% above today’s (GBX 709.5) stock price. Mediclinic International has been the topic of 19 analyst reports since February 18, 2016 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, March 14 by Investec. Citigroup upgraded Mediclinic International PLC (LON:MDC) rating on Tuesday, June 28. Citigroup has “Buy” rating and GBX 1150 price target. Macquarie Research maintained the shares of MDC in a report on Friday, May 27 with “Neutral” rating. Macquarie Research maintained the stock with “Neutral” rating in Wednesday, November 23 report. The stock has “Buy” rating given by UBS on Monday, November 21. Citigroup maintained Mediclinic International PLC (LON:MDC) on Thursday, February 18 with “Neutral” rating. Jefferies maintained the stock with “Hold” rating in Tuesday, November 29 report. On Tuesday, September 6 the stock rating was maintained by UBS with “Buy”. As per Wednesday, September 28, the company rating was maintained by Jefferies. The stock of Mediclinic International PLC (LON:MDC) has “Neutral” rating given on Tuesday, May 24 by Citigroup.
About 459,962 shares traded hands. Mediclinic International PLC (LON:MDC) has declined 20.17% since May 2, 2016 and is downtrending. It has underperformed by 25.43% the S&P500.
Analysts await M.D.C. Holdings, Inc. (NYSE:MDC) to report earnings on February, 1. They expect $0.71 EPS, up 54.35% or $0.25 from last year’s $0.46 per share. MDC’s profit will be $35.09 million for 9.48 P/E if the $0.71 EPS becomes a reality. After $0.54 actual EPS reported by M.D.C. Holdings, Inc. for the previous quarter, Wall Street now forecasts 31.48% EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.22 in 2016 Q2. Its up 0.39, from 0.83 in 2016Q1. The ratio increased, as 26 funds sold all Mediclinic International PLC shares owned while 62 reduced positions. 21 funds bought stakes while 52 increased positions. They now own 38.01 million shares or 0.55% more from 37.80 million shares in 2016Q1.
Ameriprise Fincl Incorporated has invested 0% of its portfolio in Mediclinic International PLC (LON:MDC). Teacher Retirement Sys Of Texas has invested 0% of its portfolio in Mediclinic International PLC (LON:MDC). Swiss Financial Bank holds 65,000 shares or 0% of its portfolio. Millennium Mngmt Ltd Limited Liability Company has invested 0.04% of its portfolio in Mediclinic International PLC (LON:MDC). Blackrock Ltd last reported 56,528 shares in the company. Voya Inv Management Limited holds 15,369 shares or 0% of its portfolio. Quantitative Invest Limited Company last reported 0.01% of its portfolio in the stock. Blackrock Inc last reported 0% of its portfolio in the stock. Kennedy Cap Management, a Missouri-based fund reported 305,044 shares. Citadel Advsrs accumulated 107,542 shares or 0% of the stock. Pinnacle Ltd Llc has 0% invested in the company for 33,052 shares. Fmr reported 4.24 million shares or 0.01% of all its holdings. Capstone Asset Mgmt has invested 0.01% of its portfolio in Mediclinic International PLC (LON:MDC). Inv Mngmt Of Virginia Limited Liability Company last reported 271,049 shares in the company. Old Mutual Invsts (Uk) Limited has 139,105 shares for 0.06% of their US portfolio.
Mediclinic International plc, formerly Al Noor Hospitals Group plc, is a holding company. The company has a market cap of 5.23 billion GBP. The Firm operates as an international private healthcare provider. It has a 25.94 P/E ratio. The Company’s divisions include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate.
According to Zacks Investment Research, “M.D.C. HOLDINGS, INC. is engaged in the construction, sale and related financing of residential housing and the acquisition and development of land for use in its homebuilding activities and sale to others, in the Denver, Phoenix, Maryland, Virginia, mid Atlantic region, Las Vegas, Dallas, California metropolitan areas. They are also is involved in real estate brokerage, property management, condominium conversions and fee construction of apartment and commercial buildings.”
M.D.C. Holdings, Inc., incorporated on May 17, 1985, is engaged in two primary operations, including homebuilding and financial services. The Company’s homebuilding activities consist of subsidiary companies that purchases finished lots or develop lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the name Richmond American Homes. The Company’s homebuilding activities consists of various homebuilding divisions that the Company considers to be its operating divisions. The Company’s operating divisions include West (include operating divisions located in Arizona, California, Nevada and Washington); Mountain (include operating divisions located in Colorado and Utah), and East (include operating divisions located in Virginia, Florida and Maryland, which include Pennsylvania, and New Jersey).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy